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ABSTRACT
Nicotinic acetylcholine receptors are implicated in several neu-
ropsychiatric disorders, including nicotine addiction, Alzhei-
mer’s, schizophrenia, and depression. Therefore, they repre-
sent a critical molecular target for drug development and
targeted therapeutic intervention. Understanding the molecular
mechanisms by which allosteric modulators enhance activation
of these receptors is crucial to the development of new drugs.
We used the substituted cysteine accessibility method to study
conformational changes induced by the positive allosteric mod-
ulator N-(5-chloro-2,4-dimethoxyphenyl)-N-(5-methyl-3-isox-
azolyl)-urea (PNU-120596) in the extracellular ligand binding
domain of 7 nicotinic receptors carrying the L247T mutation.
PNU-120596 caused changes in cysteine accessibility at the
inner beta sheet, transition zone, and agonist binding site.
These changes in accessibility are similar to but not identical to
those caused by ACh alone. In particular, PNU-120596 induced
changes in MTSEA accessibility at N170C (in the transition
zone) that were substantially different from those evoked by
acetylcholine (ACh). We found that PNU-120596 induced
changes at position E172C in the absence of allosteric modu-
lation. We identified a cysteine mutation of the agonist binding
site (W148C) that exhibited an unexpected phenotype in which
PNU-120596 acts as a full agonist. In this mutant, ACh-evoked
currents were more sensitive to thiol modification than PNU-
evoked currents, suggesting that PNU-120596 does not bind at
unoccupied agonist-binding sites. Our results provide evidence
that binding sites for PNU-120596 are not in the agonist-bind-
ing sites and demonstrate that positive allosteric modulators
such as PNU-120596 enhance agonist-evoked gating of nico-
tinic receptors by eliciting conformational effects that are
similar but nonidentical to the gating conformations promoted
by ACh.
Nicotinic acetylcholine receptors (nAChRs) are the proto-
typical member of the Cys-loop family of ligand-gated ion
channels that also includes GABAA, serotonin type 3 (5-HT3),
and glycine receptors. This family of receptors assembles as
heteromeric or homomeric pentamers around a central pore
(Karlin, 2002). Each subunit contains an extracellular li-
gand-binding domain (LBD), an -helical transmembrane
domain (TMD), a transition zone that couples the LBD to the
TMD, and an intracellular domain (Gay and Yakel, 2007).
Neuronal nAChRs are expressed diffusely throughout most
of the central nervous system; 7-containing receptors show
the highest levels of expression (Orr-Urtreger et al., 1997). Of
the neuronal nicotinic receptors, the homomeric 7 receptor
is implicated in neurological diseases such as schizophrenia,
Alzheimer’s Disease, and anxiety disorders (Gotti and Clem-
enti, 2004). Therefore, the 7 nicotinic receptor represents an
important therapeutic target.
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Over the last several years, there has been success in
developing synthetic positive allosteric modulators (PAMs)
for 7 nAChRs, including PNU-120596 (Bertrand and
Gopalakrishnan, 2007). These compounds are predicted to
bind away from the orthosteric agonist binding sites and
enhance gating of the receptor in the presence of agonists.
PNU-120596 is part of a growing class of PAMs that can
reopen 7 receptors from the desensitized state and slow
additional desensitization, designated as type II modulators
(Grønlien et al., 2007). By eliminating the desensitized state,
type II PAMs exert a much greater effect on 7 receptor
activation than agonists or PAMs that do not alter desensi-
tization (type I modulators).
In animal models, PNU-120596 can partially restore audi-
tory gating deficits (Hurst et al., 2005), a common symptom
of schizophrenia. Understanding the molecular mechanisms
and structural determinants of PAM action could lead to the
development of drugs for the treatment of a wide variety of
neuropsychiatric disorders. For example, structural elements
from cytisine and morphine guided the development of
varenicline, a 42 partial agonist and 7 agonist that re-
duces drug-seeking behavior and consumption of nicotine
(Mihalak et al., 2006).
To understand how different nAChR subtypes contribute
to disease states, it is crucial to understand the molecular
mechanisms by which these receptors couple the binding of
agonists and PAMs to opening of the channel. Benzodiaz-
epines, the archetypal positive allosteric modulators of
GABAA receptors, induce conformational changes in the li-
gand-binding domain of GABAA receptors (Sharkey and
Czajkowski, 2008). We have found that agonists of 7 recep-
tors induce structural transitions in the LBD, as measured
by the substituted cysteine accessibility method (SCAM) (Ly-
ford et al., 2003; McLaughlin et al., 2006, 2007). Based on the
existing data, we hypothesize that PAMs and agonists cause
similar but nonidentical conformational changes.
Here, we used SCAM to compare changes in cysteine ac-
cessibility caused by PNU-120596 and ACh. We found that
PNU-120596 induced conformational changes in the inner 
sheet, transition zone, and orthosteric site that were similar
to but not identical to those induced by ACh. We have iden-
tified mutations that either eliminate or enhance allosteric
modulation to the point of full agonism. Finally, we present
evidence that PNU-120596 does not bind at the agonist-
binding site.
Materials and Methods
Reagents. Female Xenopus laevis frogs were obtained from Xe-
nopus One (Dexter, MI) or Xenopus Express (Brooksville, FL). Meth-
anethiosulfonate (MTS) chemicals were obtained from Toronto Re-
search Chemicals (Toronto, ON, Canada). PNU-120596 was obtained
from Tocris Bioscience (Ellisville, MO). The QuikChange site-di-
rected mutagenesis kit was obtained from Stratagene (La Jolla, CA)
and the mMessage mMachine in vitro RNA transcription kit was
obtained from Ambion (Austin, TX). All other reagents for molecular
biology, oocyte dissection, and electrophysiological recordings were
obtained from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific
(Pittsburgh, PA).
Molecular Biology. The chick 7 nAChR was expressed in the
pAMV vector under the control of the T7 promoter. Mutations were
introduced into C115A/L247T receptors using the QuikChange site-
directed mutagenesis kit according to the manufacturer’s instruc-
tions, and were verified by DNA sequencing. All receptors contained
a cysteine-to-alanine mutation at position 115. Cys115 is the only
unpaired cysteine in the LBD, and the C115A mutation simplifies
the interpretation of thiol modification experiments without affect-
ing responses to ACh (McLaughlin et al., 2006) or PNU-120596. The
utility of the L247T mutation is described under Results. Capped
cRNA transcripts were made as described previously (Lyford et al.,
2003).
Construct Expression in X. laevis oocytes. X. laevis oocytes
were surgically removed as described previously (Lyford et al., 2003).
The oocytes were injected with 20 ng of 7 nAChR cRNA and were
incubated for 2 to 7 days in ND96 (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, and 5 mM Na-HEPES, pH 7.5) plus 50 mg/ml
gentamicin and 0.55 mg/ml sodium pyruvate.
Some mutants, displaying a peak current response to maximal
ACh of less than 100 nA, were coexpressed with human RIC-3
protein (resistant to inhibitors of cholinesterase) in a 1:1 (w/w) cRNA
ratio (Lansdell et al., 2005). Dose-response curves from several mu-
tant 7 receptors were generated with and without coexpression of
RIC-3. The data suggest that RIC-3 substantially increased the peak
current amplitude without major effects on the ACh EC50 values
(Supplemental Table 1).
Two-Electrode Voltage Clamp of X. laevis oocytes. Oocytes
were superfused with ESLC (96 mM NaCl, 2 mM KCl, 10 mM MgCl2,
0.1 mM CaCl2, and 10 mM HEPES-NaOH, pH 7.5), a low-Ca
2
solution that minimizes currents through Ca2-activated Cl chan-
nels. For each mutant 7 nAChR, a 5 to 7 point dose-response curve
was generated to ACh alone or with the addition of 1 M PNU-
120596 (in ESLC). Dose responses for ACh with and without PNU-
120596 were obtained from the same oocytes. Unless otherwise
noted, PNU-120596 was preapplied for 30 s and then coapplied with
ACh. For some mutant receptors, a dose-response curve was gener-
ated for the allosteric modulator in the presence of an EC30–50 dose of
ACh. All dose response curves were fit to a three-parameter Hill
equation using SigmaPlot 9.0 (Systat Software, San Jose, CA). Data
were reported as the average  S.E.M. Two-electrode voltage clamp
was performed as described previously (McLaughlin et al., 2007).
Solutions were applied by gravity perfusion with a flow rate of 3 to 5
ml/min. Oocytes were superfused with ESLC for at least 2 min
between all drug applications, and current amplitudes returned to
baseline.
To eliminate complications of run-up and run-down of current over
the course of an experiment, all oocytes were initially treated with a
maximal ACh dose 3 to 4 times consecutively. Oocytes were dis-
carded if the response to the maximal ACh dose varied by more
than  10%.
Substituted Cysteine Accessibility Method. MTS reagents
were made fresh daily in distilled H2O and stored on ice. Just before
use, the MTS reagents were diluted to the appropriate concentration
in ESLC and were applied immediately to the oocytes. 2-Aminoethyl
methanethiosulfonate (MTSEA) was our test compound to screen for
reactivity at introduced thiols. We compared the ACh dose response
curves of each mutant before and after application of a high concen-
tration of MTSEA (0.5–10 mM for 0.5–4 min). For mutants that
showed a functional effect of MTSEA, a limiting concentration of
MTSEA (0.1–100 M), yielding 20 to 50% of the maximal MTSEA
effect, was determined empirically. To measure modification rates,
the limiting concentration of MTSEA was applied repeatedly for 15
to 30 s. In experiments with PNU-120596, 1 M was preapplied for
30 s and then coapplied with the limiting concentration of MTSEA.
In experiments with agonists, an EC100 (a maximally effective con-
centration) was coapplied with the limiting concentration of MTSEA.
In all experimental conditions, the functional effect of MTSEA mod-
ification was tested with a EC50 concentration of ACh. Each appli-
cation of ACh was applied until a peak current amplitude was
obtained (15 s), and then the perfusion was switched back to ESLC
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(wash buffer). At the end of each experiment, a maximal dose of
MTSEA was applied (0.5–10 mM) to measure the effect when all
accessible thiols were modified.
Normalized current amplitudes ({It  I}/{Izero  I}, where It is
the current amplitude after the cumulative time of MTSEA expo-
sure, I is the current amplitude after the final maximal dose of
MTSEA, and Izero is the initial current amplitude before modifica-
tion) were fit to a single exponential decay (Pascual and Karlin,
1998) using SigmaPlot 9.0. The pseudo first-order rate constant was
determined and was divided by the MTSEA concentration to give the
second-order rate constant (molar1 seconds1).
Statistical Analysis. Hill equation parameters and second-order
rate constants were analyzed by one-way analysis of variance with
Tukey’s post hoc test (SigmaStat 3.0; Systat Software, San Jose, CA).
P values of 0.05 were interpreted to indicate significant differences.
Structural Models of the 7 Nicotinic Receptor. A model of
the chick 7 nicotinic receptor extracellular domain, based on the
coordinates of the Lymnea stagnalis ACh Binding Protein (Brejc et
al., 2001) was constructed as described previously (Lyford et al.,
2003; McLaughlin et al., 2006). Images of the model were generated
with Pymol (DeLano Scientific, South San Francisco, CA). For ref-
erence, Leu247 is located in the transmembrane domain, in the
pore-lining M2 helix, approximately a third of the pore’s length from
the intracellular end (Revah et al., 1991; Unwin, 2005).
Results
Effect of Mutations on Positive Allosteric Modula-
tion by PNU-120596. Figure 1 shows our homology model of
the 7 nAChR derived from the structure of the L. stagnalis
Acetylcholine Binding Protein (Brejc et al., 2001) and the
regions of interest targeted in this study. Trp148 and Trp54
are located in the agonist-binding “pocket” (the orthosteric
site). Met37, Asn52, and Met40 are located at the interface
between subunits (the inner  sheet), “below” the agonist
binding pocket. These residues were previously shown to be
good reporters of agonist-induced conformational changes
(McLaughlin et al., 2007). Glu44, Asn170, and Glu172 are
located in the “transition zone” that couples the LBD to
the TMD.
All mutants in this study contained the well characterized
leucine 247-to-threonine (L247T or L9T) mutation. L247T-
containing 7 receptors have conductance and ion selectivity
that are similar to those of the wild-type receptor but are
more sensitive to acetylcholine and exhibit slower macro-
scopic desensitization (Revah et al., 1991). L247T is a good
model system for our studies, because its large current am-
plitudes allow us to measure modification rates for cysteine
Fig. 1. Homology model of the extracellular
domain of 7 nAChR. A ribbon cartoon dis-
playing two subunits of the pentameric recep-
tor, viewed from the outside. The primary
ACh-binding subunit is shown in yellow and
the complimentary subunit is in cyan. Resi-
dues of interest are shown as sticks and are
labeled on one of the two subunits for clarity.
Met37, Met40, and Asn52 are part of the
inner  sheet (1, 2, 6). Glu44, Asn170,
and Glu172 are part of the transition zone
(loops 2 and 9). Trp54 and Trp148 are part of
the orthosteric (agonist-binding) site (6, and
behind the C loop). The residues of interest
and the surrounding amino acid sequence is
shown beneath the cartoon. The structure of
PNU-120596 is shown below the chick 7
nAChR amino acid sequence.
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substitutions with decreased functional expression levels. All
mutants also contained the C115A mutation, in which the
single unpaired cysteine in the LBD is mutated to an alanine.
This mutation, which has no effect on activation kinetics,
ligand sensitivity, or ion permeation, simplifies interpreta-
tion of cysteine modification experiments (McLaughlin et al.,
2006).
We first examined whether PNU-120596 acts as a posi-
tive allosteric modulator of C115A/L247T 7 receptors. PNU-
120596 retained its modulatory effect in the C115A/L247T
background, as measured by the ability to enhance ACh-
evoked currents in a dose-dependent manner (Fig. 2A). The
concentration of PNU-120596 that elicited a half-maximal
modulation (when applied with an EC30–50 concentration of
ACh) was 257  22 nM (Fig. 2A), a value that is similar to
that reported for wild-type 7 receptors (216  64 nM; Hurst
et al., 2005). This suggests that the C115A/L247T mutations
do not significantly alter the affinity of PNU-120596 for the
7 nicotinic receptor.
PNU-120596 (1 M) caused a left-shift of the ACh dose-
response curve of C115A/L247T 7 receptors and a signifi-
cant decrease in the EC50 for ACh (Fig. 2B, Table 1). In
contrast to the responses of wild-type 7 receptors (Hurst et
al., 2005), PNU-120596 did not cause a significant change in
the current amplitudes of C115A/L247T 7 receptors evoked
at maximal ACh concentrations. We speculate that the
L247T mutation increased the “gating constant” of the recep-
tors (Colquhoun, 1998), lowering the ACh EC50 compared
with wild-type receptors. For receptors with a low gating
constant, such as wild-type 7 receptors, a PAM could in-
crease the maximal response, decrease the EC50, or both. In
contrast, for receptors with a high gating constant, such as
L247T-containing 7 receptors, we expect PAMs to affect
EC50 alone, because the maximal response to agonist is al-
ready near 1 (Colquhoun, 1998).
A unique feature of PNU-120596 is the ability to reactivate
desensitized 7 receptors in the presence of agonist, a feature
defined as type II modulation (Hurst et al., 2005; Grønlien et
al., 2007). Therefore, we determined whether PNU-120596
could reactivate C115A/L247T 7 receptors after slow desen-
sitization. A representative trace is shown in Fig. 2C. As
expected, C115A/L247T receptors showed partial desensiti-
zation during continuous application of an EC100 concentra-
tion of ACh (100 M, a maximally effective concentration),
reaching a plateau at 48.2  0.02% desensitization by 87.5 
7.0 s (n  5). Then, application of an EC100 concentration of
PNU-120596 (1 M) after partial desensitization reactivated
the C115A/L247T receptors (n  5), consistent with type II
modulation. The continuous application of ACh and PNU-
120596 completely blocked slow desensitization of C115A/
L247T receptors, as observed in wild-type 7 receptors
(Grønlien et al., 2007). The ability of PNU-120596 to reacti-
vate partially desensitized C115A/L247T receptors and pre-
vent subsequent desensitization did not depend on the ACh
concentration (data not shown). We conclude that the C115A/
L247T mutations do not alter the affinity or kinetics of PNU-
120596 (Fig. 2, A and C), only the ability to enhance peak
current amplitude (Fig. 2B), which we attribute to enhanced
gating of the C115A/L247T receptors. This interpretation is
supported by macroscopic and single-channel analysis, show-
ing that effects on apparent desensitization by mutations at
L9 in other Cys-loop receptors can be explained by increases
in mean open time alone (Filatov and White, 1995; Bianchi
and Macdonald, 2001). Therefore, 7 receptors containing
the C115A/L247T mutation are a reasonable model to exam-
ine conformational transitions underlying allosteric modula-
tion by PNU-120596.
For all of the cysteine mutations used in this study, we
generated ACh concentration-response curves to probe for
possible deleterious effects of the individually introduced
cysteines on channel function. Most cysteine mutations gen-
Fig. 2. PNU-120596 is a positive allosteric modulator of C115A/L247T 7
receptor and elicits opening from a partially desensitized state. A, PNU-
120596, at the concentrations shown, was applied with an EC50 dose of
ACh (2–3 M). Positive allosteric modulation was observed as a signifi-
cant enhancement of ACh-evoked current (189  18%, n  5). The EC50
for PNU-120596 was 257  22 nM (n  5). B, ACh was applied with an
EC100 dose of PNU-120596 (1 M). Positive allosteric modulation was
observed as a significant reduction in the EC50 for ACh (Table 1). Data
are fit to the Hill equation and are the mean value  S.E.M, normalized
to the maximal value of the Hill equation fit of each data set. C, a
representative trace showing that an EC100 dose of PNU-120596 (1 M)
is sufficient to reactivate partially desensitized C115A/L247T receptors
(n  5). Coapplication of ACh and PNU-120596 is also sufficient to
completely inhibit desensitization, and responses are reversible when
both compounds are washed out.
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erated ACh EC50 values that were not significantly different
from the parent C115A/L247T receptor (Table 1), suggesting
that the introduced mutations were well tolerated. Two mu-
tations at the orthosteric site (W54C and W148C) signifi-
cantly increased the ACh EC50 compared with the parent
C115A/L247T receptor, as expected for residues required for
the binding of agonists or in close proximity to the binding
site (Brejc et al., 2001). We found that two mutants (N52C
and W148C) were unexpectedly activated by PNU-120596
alone. The EC50 values for PNU-120596 activation were
340  20 nM (n  3) and 450  10 nM (n  3) for N52C and
W148C mutant receptors, respectively. Our interpretation is
that the N52C and W148C mutations enhance the ability of
PNU-120596 to induce conformational changes such that it
can directly gate these mutant receptors.
Because a binding site for divalent cation modulators has
been proposed in the transition zone (Galzi et al., 1996), we
also introduced mutations at positions Glu44 and Glu172 to
test whether the putative divalent cation binding site is
required for modulation by PNU-120596. We found that one
mutation in the transition zone (E172C) and one mutation in
the inner  sheet (M37C) eliminated positive allosteric mod-
ulation by PNU-120596 (Table 1). These data provide evi-
dence that Met37 and Glu172 are required for binding of
PNU-120596 and/or PNU-120596-induced changes in gating.
PNU-120596 Causes Structural Transitions within
the Extracellular Ligand Binding Domain Similar to
Those Caused by Acetylcholine. To explore conforma-
tional changes in 7 receptors evoked by PNU-120596, we
examined PNU-120596-dependent changes in the rate of
MTSEA modification of cysteines introduced in the LBD. The
ability of ligands to alter the rate of MTS modification of
introduced thiols is interpreted as 1) steric interference be-
tween the ligand and the MTS reagent, 2) a conformational
change of the introduced thiol induced by that ligand that
changes the surface accessibility of the thiol, and/or 3) a
conformational change induced by the ligand in the environ-
ment near the introduced thiol that alters its local electro-
static environment (Akabas et al., 1992; McLaughlin et al.,
2007).
It is important to note that SCAM measures the time-
averaged conformational transition of the receptor, including
closed, open, desensitized, and multiple intermediate states.
Because the L9T mutation increases the open time of 7
receptors (Revah et al., 1991; Filatov and White, 1995), we
assume that the conformational changes measured in the
presence of ACh are dominated by those relating to activa-
tion over those relating to desensitization. However, we can-
not rule out the effects of our introduced cysteines and L247T on
the conformational pathways associated with desensitization.
Fig. 3 shows an example of the protocol used to measure
the thiol modification rate (E44C). Fig. 3A shows an experi-
ment from a single oocyte in which a submaximal concentra-
tion of MTSEA (1 M) was applied between test applications
of ACh (see Materials and Methods). The effect of covalent
modification was a decrease in ACh-evoked currents. Fig. 3B
shows an experiment in which 1 M PNU-120596 was pre-
applied and then coapplied with MTSEA (1 M) between test
applications of ACh. For clarity, only the ACh-evoked cur-
rents that were used to determine the rate of modification are
shown. For each experiment, peak ACh-evoked current am-
plitudes were plotted versus the cumulative time of exposure
to MTSEA (Fig. 3C). Pseudo–first-order rate constants ob-
tained from the fits of the data to a single exponential equa-
tion were divided by the concentration of MTSEA to yield the
second-order rate constants (k2) shown in Table 2.
Using this protocol, we determined the second-order rate
constants for modification of three residues in the inner 
sheet (M37C, M40C, N52C). Fig. 4A shows the mean second-
order rate constants measured in the presence of MTSEA
alone (control), MTSEA plus ACh, and MTSEA plus PNU-
120596. PNU-120596 and ACh each caused a 7- to 9-fold
reduction in the modification rate of M37C and a 5- to 7-fold
reduction in the modification rate of M40C (Fig. 4B). The
modification rates in the presence of ACh or PNU-120596
were significantly different from control but were not signif-
icantly different from each other. Thus, without activating
these receptors, PNU-120596 caused changes in the accessi-
bility or electrostatic environment of M37C and M40C that
were similar to those caused by ACh (McLaughlin et al.,
2007). PNU-120596 decreased the rate of modification of
M37C, even though receptors containing this mutation were
not positively modulated by PNU-120596 (Table 1). This
result demonstrates that PNU-120596 can elicit conforma-
tional changes in the inner  sheet in the absence of a
modulatory effect. Because Met37 or Met40 are not part of
the agonist binding site, it is unlikely that steric interference
between ligand and MTSEA is responsible for the decreased
TABLE 1
Summary of ACh dose response data
Mutant ACh EC50 Imax Hill Coefficient n ACh EC50  1 M PNU-120596 n Effect
a
M A M
C115A/L247T background 2.4  0.23 6.4  0.64 2.8  0.25 10 0.22  0.09 3 PAM
Inner  sheet
M37C 4.5  1.30 0.4  0.12 1.3  0.10 10 1.6  0.18 7 N.E.
M40C 6.7  0.70 2.2  0.47 1.4  0.11 16 0.58  0.17 4 PAM
N52C 0.79  0.20 0.31  0.08 0.68  0.07 13 N.D.b
Transition zone
E44C 7.2  0.56 4.6  0.39 2.6  0.31 10 2.5  0.37 3 PAM
N170Cc 12  1.4 1.3  0.24 1.6  0.12 15 2.6  0.56 3 PAM
E172Cc 30  2.0 0.74  0.11 2.4  0.10 16 41  5.3 3 N.E.
Agonist-binding site
W54C 88  9.7 2.3  0.40 1.6  0.04 12 15  5.1 5 PAM
W148Cc 205  28 3.5  0.52 1.5  0.06 11 N.D.b
N.E., no effect; N.D., not determined.
a Based on statistically significant differences between ACh EC50 with and without 1 M PNU-120596 (P  0.05).
b Value not determined because of agonism observed with PNU-120596.
c Coexpression with human RIC-3 (see Materials and Methods).
Conformational Effects of PNU-120596 on 7 nAChRs 257
modification rates observed at these positions. In contrast,
PNU-120596 did not cause a difference in the rate of modi-
fication of N52C (Fig. 4, A and B). Although, ACh increased
the rate of MTSEA modification of N52C (McLaughlin et al.,
2007), PNU-120596 did not cause a significant change. Thus,
PNU-120596 caused some but not all of the changes in thiol
accessibility in the inner -sheet caused by ACh. To verify
that the conformational changes studied in L247T 7 recep-
tors were similar to those in wild-type 7 receptors (WT), we
also studied cysteine accessibility of M40C constructed in the
WT background. The rates of MTSEA modification of M40C/
WT, with and without ACh, were similar to those measured
in the C115A/L247T background (Supplemental Fig. 1). This
suggests that the changes in accessibility that we measure
are independent of the C115A/L247T mutation.
Next, we determined the second order rate constants for
the modification of three residues in the transition zone
(E44C, N170C, and E172C). Fig. 5A shows the mean second-
order rate constants measured in the presence of MTSEA
alone (control), MTSEA plus ACh, and MTSEA plus PNU-
120596. We observed differential effects of PNU-120596 in all
three mutant receptors. PNU-120596 and ACh each de-
creased the rate of MTSEA modification of E44C by 8- and
21-fold, respectively (Fig. 5, A and B). PNU-120596 and
ACh both decreased the rate of modification of E172C by 2- to
5-fold, even though receptors containing this mutation were
not positively modulated by PNU-120596 (Table 1). This
result demonstrates that PNU-120596 can elicit conforma-
tional changes in the transition zone in the absence of a mod-
ulatory effect. The rate of MTSEA modification of N170C was
altered differently by PNU-120596 and ACh. PNU-120596
significantly decreased the rate of modification, whereas ACh
increased the rate of modification. Overall, these data show
that PNU-120596 induces conformational changes at Glu44
and Glu172 that are similar to those induced by ACh, but
PNU-120596-induced changes at Asn170 are different from
those induced by ACh.
We also measured the combined effects of ACh plus PNU-
120596 on MTSEA modification at introduced cysteines in
the transition zone (E44C, N170C, and E172C). At E44C and
E172C, the combination of PNU-120596 and ACh caused a
larger effect than that caused by either ACh or PNU-120596
alone (Fig. 5, Table 2). At N170C, PNU-120596 and ACh had
opposite effects on the rate of MTSEA modification. The
simultaneous application of both reagents gave a rate of
MTSEA modification that was not significantly different
from control. In this respect, combined effects of PNU-120596
and ACh led to a net cancelation of each individual effect.
Because the vestibule of the LBD of nicotinic receptors is
predicted to be highly electronegative (Unwin, 2005), we also
examined the rates of MTS modification using anionic MTS
reagents (Supplemental Data Figs. 2–4). We found that
MTSEA modified E44C much faster than MTSCE and
MTSES (Supplemental Data Fig. 3), even after accounting
for the lower intrinsic rates of reaction by MTSCE and
MTSES (Supplemental Fig. 2). In addition, the effect of ACh
on the rate of MTSEA modification was much greater than
the effect of ACh on the rate of MTSCE modification. Modi-
fication of M40C by either MTSES or MTSCE was too slow to
measure (Supplemental Fig. 4). These results provide addi-
tional evidence for a highly negative electrostatic environ-
ment lining the vestibule of AChRs and suggest that changes
in the electrostatic environment affect modification rates at
residues in the inner  sheet and transition zone.
Fig. 6 shows second-order rate constants of MTSEA mod-
ification of two residues in the orthosteric agonist binding
site (W54C and W148C). ACh slowed the rate of modifica-
tion of W54C, which agrees with previously published re-
sults on wild-type 7 receptors (Gay et al., 2008). However,
PNU-120596 did not significantly reduce the rate of mod-
ification at W54C (Fig. 6A). ACh and PNU-120596, acting
as agonists (Table 1), both significantly slowed the rate of
modification of W148C (Fig. 6A). Because the aromatic
side chains of Trp54 and Trp148 are both known to be part
Fig. 3. PNU-120596 slows the rate of MTSEA modification at E44C. A,
successive ACh-evoked currents before and after the addition of a sub-
maximal concentration of MTSEA (1 M, 15-s exposures). After four
successive applications, the endpoint of MTSEA modification was deter-
mined by a prolonged application of 500 M MTSEA for 60 s. Washes of
1 to 2 min between drug applications are not shown. B. the same protocol
as A, with a 30-s pre-exposure to 1 M PNU-120596 followed by coappli-
cation of 1 M PNU-120596 with MTSEA. C, normalized peak current
amplitudes from a single experiment are plotted against cumulative
MTSEA exposure. The calculated pseudo–first-order rate constants from
these experiments are 0.0299 s1 for control (A), and 0.0169 s1 in the
presence of PNU-120596 (B). Second-order rate constants (k2) are calcu-
lated from these values and are displayed in Table 2.
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of the ligand-binding site, it is likely that steric occlusion
by ACh is at least partially responsible for the slowing of
modification of these Cys mutants. Slowing of modification
of W148C by PNU-120596 could also be explained by steric
hindrance, if PNU-120596 binds at unoccupied agonist
binding sites, analogous to the binding site for benzodiaz-
epines at the - subunit interface of GABAA receptors
(Günther et al., 1995; Amin et al., 1997). Acetylcholine (Mr
146) contains a positively charged choline group that
makes -cation interactions with the agonist-binding site
(Zhong et al., 1998). PNU-120596 (Mr 312) is a urea analog
flanked by isoxazole and chlorodimethoxyphenyl groups
(Hurst et al., 2005). Recent evidence, however, suggests
that PAMs of 7 receptors bind to sites in the TMD (Ber-
trand et al., 2008; Young et al., 2008), and thus slowing of
W148C modification by PNU-120596, could be explained
by an allosteric effect at the ligand-binding pocket, per-
haps including partial closure of loop C.
To distinguish between these possibilities we took ad-
vantage of an unexpected observation: introduction of
W148C in the C115A/L247T parent receptor converted
PNU-120596 from a positive allosteric modulator to a full
agonist (Table 1 and Fig. 7A). The phenotype of this recep-
tor is useful because it allows us to compare the effects of
covalent modification with MTS reagents on either ACh- or
PNU-120596-evoked gating at the well defined agonist-
binding site. If PNU-120596 activates the receptors via
binding to the orthosteric agonist binding site, we expect
that covalent modification of W148C in the agonist binding
pocket to disrupt activation by both ACh and PNU-120596
similarly via steric effects on ligand binding. If
PNU-120596 does not activate W148C mutants by binding
at the agonist binding site, then PNU-evoked currents
should be less sensitive to covalent modification of W148C
than ACh-evoked currents. For these experiments, we
used two MTS reagents of different size and charge to
determine moiety-dependent affects on ACh and PNU-
evoked current at W148C. MTSEA adds a positively
charged ethyl amine to thiols at physiological pH and is
comparatively small. MTSEA-biotin adds a neutral, bulky
ring structure to thiols and is comparatively large.
Fig. 7B shows representative ACh- and PNU-120596-
evoked currents before and after modification of W148C by
MTSEA (100 M for 60 s). This exposure to MTSEA was
sufficient to completely eliminate ACh-evoked current, but it
had no effect on currents evoked by PNU-120596. If we
assume that modification of a binding site residue interferes
with activation by steric interference with ligand, then this
result implies that PNU-120596 activates receptors via a site
distinct from the orthosteric site. However, an alternative
explanation is that the two ligands interact with a different
set of “contact points” in the binding pocket, and those for
PNU-120596 are removed from the ethyl amine adduct at
Trp148. To test this, we examined the effect of MTSEA-
biotin, which modifies the thiol with a bulky ring structure.
Fig. 7C shows representative ACh- and PNU-120596-evoked
currents before and after modification of W148C by MTSEA-
biotin (4 M for 60 s). This exposure of MTSEA-biotin was
sufficient to reduce ACh-evoked current by 70% but had no
significant effect on the magnitude of currents evoked by
PNU-120596. Modification of the agonist binding site by
MTSEA-biotin slowed the kinetics of PNU-120596-depen-
dent activation (Fig. 7C), suggesting that there are allosteric
conformational changes at the agonist binding site during
activation by PNU-120596. The results from multiple exper-
iments are summarized in Fig. 7D. Covalent modification of
W148C by MTSEA and MTSEA-biotin had a significantly
greater effect on ACh-evoked current than on PNU-120596-
evoked currents (P  0.01). This observation provides evi-
dence that PNU-120596, although behaving as an agonist,
does not interact with the agonist-binding site of 7 recep-
tors. Our interpretation is that PNU-120596 induces confor-
mational changes at the agonist-binding site through allo-
steric mechanisms, rather then steric occlusion, because
occlusion is predicted to impair both ACh and PNU-evoked
currents similarly.
Discussion
In this study, we provide evidence that the positive
allosteric modulator PNU-120596 causes conformational
changes in the LBD of 7 nicotinic receptors that partially
overlap with those caused by ACh. We focused on mapping
the structural transitions of PAMs in three regions of the
LBD: 1) The inner  sheet, 2) the transition zone, and 3) the
orthosteric site (Fig. 1). A homology model of the LBD of the
7 receptor, based on the structure of ACh binding protein,
was used to guide our experiments (Brejc et al., 2001; Lyford
et al., 2003).
The inner  sheet, composed of the 1, 2, and 6 strands,
TABLE 2
Second-order rate constants for MTSEA modification of receptors carrying Cys substitutions in the extracellular domain of 7 nAChR
Numbers in parentheses represent n.
Mutant Control MTSEA  ACh MTSEA  PNU-120596 MTSEA  ACh  PNU-120596
M1s1
Inner  sheet
M37C 2470  310 (12) 333  152* (6) 271  104* (7)
M40C 16,100  2370 (15) 2090  748* (5) 3030  313* (5)
N52C 250  68 (8) 1320  238* (9) 390  118† (4)
Transition zone
E44C 33,700  6540 (8) 1460  505* (8) 4180  637* (5) 312  19* (5)
N170C 3160  392 (7) 5730  682* (7) 818  114*† (10) 3660  115 (4)
E172C 12,900  1560 (9) 3450  470* (6) 2830  410* (7) 1710  310* (7)
Agonist-binding site
W54C 9500  1330 (6) 4030  770* (5) 6080  920 (4)
W148C 45,900  7640 (9) 3010  1100* (6) 8830  1320* (6)
* Statistically different from control (P  0.05).
† Statistically different from  ACh (P  0.05).
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resides at the interface between two subunits (Fig. 1). In this
study, we found that PNU-120596 caused reductions in the
rate of modification of M37C and M40C that were similar to
those caused by ACh (Fig. 4, Table 2; McLaughlin et al.,
2007). The similarity in the effects on cysteine modification
at M37C and M40C suggests that PAMs and agonists induce
similar conformational changes in the LBD of 7 receptors.
We have provided the first evidence that PAMs of 7 recep-
tors enhance gating by causing some of the same structural
transitions in the LBD as ACh.
The transition zone, composed of loops from the LBD (loop
2, loop 9, and the Cys loop) and the TMD (pre-M1 sequence
and M2-M3 linker), is positioned to convey structural rear-
rangements caused by agonist binding in the LBD to the
channel gate in the TMD (Bouzat et al., 2004). Therefore, we
examined the effect of PNU-120596 on the rate of MTSEA
modification at three reporter residues within the transition
zone (E44C, N170C, and E172C), which is also a proposed
site of modulation by divalent cations (Galzi et al., 1996).
PNU-120596 reduced the rate of MTSEA modification at all
three positions (Fig. 5, Table 2). At N170C, PNU-120596
decreased the accessibility of the substituted cysteine,
whereas ACh caused an increase. The application of both
compounds offset each other at N170C. Overall, the changes
in cysteine accessibility in the transition zone caused by ACh
and PNU-120596 were similar but not identical.
It is noteworthy that positive modulation of ACh-evoked
currents by PNU-120596 was lost in the E172C mutant (Ta-
ble 1), but PNU-120596 still caused a decrease in thiol acces-
sibility at this position (Fig. 5). One explanation is that the
PNU-120596 binding site includes Glu172, and the intro-
duced cysteine (E172C) eliminates allosteric modulation but
not binding. In this scenario, the observed reduction in the
rate of MTSEA modification at E172C is due to physical
occlusion by PNU-120596 of the substituted cysteine at the
putative binding site. An alternative explanation is that
PNU-120596 binds to a site outside of the transition zone,
away from Glu172, and the observed reduction in the rate of
E172C modification is due to conformational changes in-
duced there. In this scenario, the binding of PNU-120596 is
unaffected and can still induce conformational changes, but
the electrostatic coupling within the transition zone (Xiu et
Fig. 4. PNU-120596 differentially alters the rate of MTSEA modification
at inner  sheet residues. A, mean second-order modification rate con-
stants (k2), calculated using the protocol outlined in Fig. 3, at three
residues in the inner  sheet, M37C, M40C, and N52C. Mean values
for MTSEA alone (control), MTSEA plus ACh, and MTSEA plus PNU-
120596 are shown, plotted on a log scale. PNU-120596 slows the rate of
modification at M37C and M40C compared with control but has no
effect at N52C. , rate was significantly different from control (P  0.05).
B, a plot of the second-order rate constant ratios. The average rate from
each experimental condition is divided by the average control rate for
each residue. Positive values represent an acceleration of the rate of
modification, and negative values represent a reduction in the rate of
modification.
Fig. 5. PNU-120596 differentially alters the rate of MTSEA modification
at residues in the transition zone. A, mean second-order modification rate
constants (k2) of at three residues in the transition zone, E44C, N170C,
and E172C. PNU-120596 significantly reduces the rate of modification at
E44C and N170C. PNU-120596 significantly reduces the rate of modifi-
cation at E172C, despite the lack of positive allosteric modulation at this
residue (Table 1). At N170C, the rate of modification in the presence of
PNU-120596 is significantly slower than in the presence of ACh. , rate
was significantly different from control (P  0.05). B, a plot of the
second-order rate constant ratios. Note that PNU-120596 slows the rate
of modification of N170C whereas ACh increases the rate of modification.
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al., 2005) is sufficiently disrupted by the cysteine mutation
that the induced conformational changes no longer enhance
receptor gating.
Fiinally, we examined the effect of ACh and PNU-120596
on the rate of MTSEA modification at two residues in the
orthosteric site (Trp54 and Trp148) (Fig. 6). Viewed from a
structural perspective, these residues occupy two distinct
locations within the agonist binding site. Trp148 is part of
the principal subunit (Fig. 1, yellow subunit). It lines the
back wall of the agonist binding site and makes contact with
agonists and competitive antagonists (Celie et al., 2004; Han-
sen et al., 2005). Trp54 is part of the complimentary subunit
and sits on the edge of the agonist binding site (Fig. 1, cyan
subunit) (Brejc et al., 2001). ACh reduced the rate of MTSEA
modification at these positions. In our interpretation, ACh
reduces covalent modification at W148C by physically block-
ing access to the introduced cysteine. On the other hand,
because carbamylcholine does not contact Trp54 (Celie et al.,
2004), we hypothesize that ACh induces a short-range con-
formational change that makes W54C less accessible to co-
valent modification. The ACh-dependent effect at W54C
agrees with previously published work on wild-type 7 re-
ceptors (Gay et al., 2008). PNU-120596 does not significantly
affect the rate of MTSEA modification at W54C, but reduced
the rate of MTSEA modification at W148C, suggesting that
PNU-120596 induces allosteric conformational changes in the
center of the agonist binding pocket, but not on the periphery.
We found unexpectedly that PNU-120596 was a full ago-
nist of W148C receptor in C115A/L247T-containing 7 recep-
tors (Fig. 7A). One explanation is that the introduced cys-
teine allowed partial closure of the C-loop and lowered the
activation energy sufficiently to allow PNU-120596 to acti-
vate the receptor and at the same time increased energetic
barriers to ACh binding. The C-loop is a dynamic and flexible
region that acts as a hinge of the orthosteric site (Hansen et
Fig. 6. PNU-120596 slows the rate of MTSEA modification at W148C but
not W54C in the orthosteric site. A, mean second-order rate constants (k2)
were calculated at two residues in the transition zone, W54C and W148C.
, rate was significantly different from control (P  0.05). B, a plot of the
second-order rate constant ratios.
Fig. 7. Covalent modification of
W148C in the orthosteric site does not
affect agonism by PNU-120596. A,
PNU-120596 acts as a full agonist of
W148C/C115A/L247T 7 receptors.
Hill parameter fits for activation by
ACh are in Table 1. For PNU-120596,
the EC50 is 0.45  0.01 M, Imax is
3.87  0.65 A, and Hill coefficient 
6.79  0.81 (n  3). PNU-evoked cur-
rents are normalized to peak ACh-
evoked current (I/IACh). B, representa-
tive traces for 3 mM ACh and 3 M
PNU-120596 shown before (black)
and after (red) application of 100 M
MTSEA for 60 s. C, representative
traces for 3 mM ACh and 3 M PNU-
120596 shown before (black) and af-
ter (red) application of 4 M MTSEA-
biotin for 60 s. D, summary data for
the effects of covalent modification of
W148C with MTSEA (n  8) and
MTSEA-biotin (n  10) on ACh and
PNU-evoked currents. Bars represent
the percentage of ACh or PNU-evoked
current after MTS modification rela-
tive to the control currents before
modification (Iafter/Ibefore). Both MTSEA
and MTSEA-biotin caused a signifi-
cantly greater reduction in ACh-
evoked currents than PNU-evoked
currents ( P  0.01).
Conformational Effects of PNU-120596 on 7 nAChRs 261
al., 2005; Venkatachalan and Czajkowski, 2008). The EC50
for ACh-dependent activation of the W148C mutant receptor
was increased 100-fold (Table 1), as expected for a receptor
with a mutation of an important aromatic residue of the
agonist-binding pocket (Brejc et al., 2001). We took advan-
tage of this phenotype to test whether PNU-120596’s ability
to alter cysteine accessibility was due to allostery or steric
occlusion. Because ACh-evoked currents are more sensitive
to covalent modification by different MTS reagents than
PNU-evoked currents (Fig. 7), we conclude that PNU-120596
induces conformational changes at this position through an
allosteric mechanism. A chemically related PAM, NS1738,
does not affect equilibrium binding of 125I--bungarotoxin,
also suggesting that it does not interact with the agonist
binding site (Timmermann et al., 2007). Recent work with
chimeric 7 nAChR/5-HT3 receptors and mutagenic studies
suggests a binding site in the transmembrane domain for
PNU-120596 and LY-2087101 (Bertrand et al., 2008; Young
et al., 2008). These data suggest that PNU-120596 and other
modulators of 7 receptors bind at a conserved site within
the transmembrane domain and cause conformational
changes in the LBD to enhance gating of the receptor.
In the Monod/Wyman/Changeux model of allostery, posi-
tive allosteric modulators of ligand-gated ion channels en-
hance activation by stabilizing the protein in the open state
(Bertrand and Gopalakrishnan, 2007). Our results provide
the first evidence that that PNU-120596 promotes activation
of 7 receptors by causing some (but not all) of the same
conformational changes in the LBD associated with agonists.
We have previously shown that permeable divalent cations,
which do not alter desensitization, also induce conforma-
tional changes in the LBD that are similar to those induced
by agonists (McLaughlin et al., 2009). Our work adds to a
growing body of literature of both convergent and divergent
conformational changes during gating of Cys-loop receptors
(Chang and Weiss, 2002; Pless et al., 2007; Sharkey and
Czajkowski, 2008; Zhang et al., 2009).
Recent work suggests that the mechanisms of closed-to-
open conformational changes induced by different agonists
and of unliganded receptors are completely conserved regard-
less of the agonist applied; only the kinetics of the C-O
transitions are affected (Purohit and Auerbach, 2009). Al-
though most of our data with PNU-120596 agrees with this
idea, modulation and rate measurements for the N170C mu-
tant seem to be an exception. For this mutant, PNU-120596
slows the rate of modification, whereas ACh increases it (Fig.
5). Thus, each ligand stabilizes a population of conforma-
tional intermediates that are distinct from each other and
from the resting unliganded state(s). A model in which C-O
transitions occur via a single pathway would predict that
PNU-120596 and ACh would cause similar changes in acces-
sibility at all residues. If there is a single path, then the
observation that PNU-120596 causes a change in accessibil-
ity of N170C opposite to that caused by ACh suggests that
the receptor would be stabilized in closed intermediate states
further away from the open state, and PNU-120596 would be
unable to enhance the conserved C-O transition. But PNU-
120596 still acts as a positive allosteric modulator of N170C
receptors, suggesting that PNU-120596 induces conforma-
tional changes along alternative pathways that lower ener-
getic barriers to activation and lead to positive modulation.
The differences between the conformational intermediates
induced by PNU-120596 and those induced by ACh are likely
to be subtle, because they are not as apparent at other cys-
teine mutants.
In conclusion, we have shown that PNU-120596 and ACh
induce a set of overlapping structural transitions in the ex-
tracellular ligand-binding domain. Our results indicate that
PAMs such as PNU-120596 enhance gating of ligand-gated
ion channels by inducing some of the same structural tran-
sitions caused by agonists. In addition, we have identified
mutations in the transition zone that eliminate modulation
of 7 nicotinic receptors by PNU-120596 via decoupling be-
tween the LBD and TMD. We have provided evidence that
PNU-120596 does not bind to unoccupied agonist-binding
site(s). The PAM-induced changes in receptor kinetics, al-
though not usually sufficient to activate receptors, would
lower the energy barriers to agonist-induced activation by
both enhancing the agonist-evoked C-O transitions as well as
alternate transitions. This process would “prime” the recep-
tors to undergo a gating transition, allowing more of the
energy of agonist binding to drive changes in the conforma-
tional equilibrium toward activation (Jackson, 1989).
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